Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer.

Autor:	Whatcott CJ; Clinical Translational Research Division, The Translational Genomics Research Institute, Phoenix, Arizona. cwhatcott@tgen.org hhan@tgen.org., Diep CH; Clinical Translational Research Division, The Translational Genomics Research Institute, Phoenix, Arizona., Jiang P; Halozyme Therapeutics, San Diego, California., Watanabe A; Integrated Cancer Genomics Division, The Translational Genomics Research Institute, Phoenix, Arizona., LoBello J; Integrated Cancer Genomics Division, The Translational Genomics Research Institute, Phoenix, Arizona., Sima C; Computational Biology Division, The Translational Genomics Research Institute, Phoenix, Arizona., Hostetter G; Laboratory of Analytical Pathology, The Van Andel Research Institute, Grand Rapids, Michigan., Shepard HM; Halozyme Therapeutics, San Diego, California., Von Hoff DD; Clinical Translational Research Division, The Translational Genomics Research Institute, Phoenix, Arizona., Han H; Clinical Translational Research Division, The Translational Genomics Research Institute, Phoenix, Arizona. cwhatcott@tgen.org hhan@tgen.org.
Jazyk:	angličtina
Zdroj:	Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2015 Aug 01; Vol. 21 (15), pp. 3561-8. Date of Electronic Publication: 2015 Feb 18.
DOI:	10.1158/1078-0432.CCR-14-1051
Abstrakt:	Purpose: Pancreatic ductal adenocarcinoma (PDAC) is characterized by high levels of fibrosis, termed desmoplasia, which is thought to hamper the efficacy of therapeutics treating PDAC. Our primary focus was to evaluate differences in the extent of desmoplasia in primary tumors and metastatic lesions. As metastatic burden is a primary cause for mortality in PDAC, the extent of desmoplasia in metastases may help to determine whether desmoplasia targeting therapeutics will benefit patients with late-stage, metastatic disease. Experimental Design: We sought to assess desmoplasia in metastatic lesions of PDAC and compare it with that of primary tumors. Fifty-three patients' primaries and 57 patients' metastases were stained using IHC staining techniques. Results: We observed a significant negative correlation between patient survival and extracellular matrix deposition in primary tumors. Kaplan-Meier curves for collagen I showed median survival of 14.6 months in low collagen patients, and 6.4 months in high-level patients (log rank, P < 0.05). Low-level hyaluronan patients displayed median survival times of 24.3 months as compared with 9.3 months in high-level patients (log rank, P < 0.05). Our analysis also indicated that extracellular matrix components, such as collagen and hyaluronan, are found in high levels in both primary tumors and metastatic lesions. The difference in the level of desmoplasia between primary tumors and metastatic lesions was not statistically significant. Conclusions: Our results suggest that both primary tumors and metastases of PDAC have highly fibrotic stroma. Thus, stromal targeting agents have the potential to benefit PDAC patients, even those with metastatic disease. (©2015 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu